Detailed Narrative
Q1 FY27 Performance Overview and Growth Drivers
Alivus Life Sciences reported a revenue from operations of INR640 crores for Q1 FY27, marking a 6.4% year-on-year growth. This performance was particularly encouraging as it was achieved despite a significant 52.6% decline in the GPL business, which was attributed to inventory rationalization. The overall growth was primarily driven by the strong execution across the non-GPL portfolio, which delivered a robust 26.5% year-on-year growth. Management expressed confidence in the resilience of their business model and the growing strength of their broader portfolio.
Profitability and Margin Expansion
The company demonstrated significant profitability improvements in Q1 FY27. Gross profit increased by 16.3% year-on-year to INR385 crores, with gross margins expanding by 510 basis points year-on-year to 60.2%. This was primarily due to a favorable product mix and successful new launches. EBITDA also saw a substantial increase of 29.1% year-on-year to INR234 crores, leading to an EBITDA margin of 36.6%, a 650 basis points improvement year-on-year, supported by enhanced operational efficiencies and forex gains. PAT stood at INR160 crores, with PAT margins at 25%.
Segmental Performance and Outlook
The non-GPL business was a key growth driver, delivering 26.5% year-on-year growth, fueled by new product launches and strong demand across all geographies. The CDMO business recorded a 3.8% year-on-year growth, with management expecting it to gain momentum in the second half of the year with contributions from newly added projects. While the GPL business experienced a 52.6% decline in Q1, it is expected to remain flattish for the full FY27, with performance skewed towards H2. CVS and CNS therapies contributed 58% to the top line, and chronic therapies accounted for 74%.
Capex and Capacity Expansion Plans
Alivus incurred a capex of INR85 crores in Q1 FY27 and plans for approximately INR540 crores for the full FY27. The Solapur facility, though slightly delayed, is expected to be operational in early Q3 FY27. Construction at the Taloja R&D center is on schedule. The company is also expanding capacity at Dahej to 160KL and Ankleshwar to 110KL. Management emphasized a calibrated approach to capacity expansion, particularly for Solapur, to ensure proper regulatory audits and avoid under-absorption.
R&D and Product Pipeline
R&D expenditure for Q1 FY27 was INR24 crores, representing 3.7% of sales. The company's pipeline remains robust with 617 DMF and CEP filings globally as of June 30. The high-potent API portfolio includes 29 products in the active grid, targeting an $82 billion market, with 13 validated, 7 in advanced development, and 9 in lab development stages. Management expects R&D spend to stabilize around 4% of sales, focusing on new API development and second-generation processes to maintain margins.
Capital Allocation and Liquidity
The company continues to maintain a debt-free status, generating a strong free cash flow of INR90 crores in Q1 FY27. Cash and cash equivalents, including short-term investments, stood at INR880 crores as of June 30, 2026. Regarding acquisition strategy, Alivus is actively looking for synergistic opportunities that add greater value, aiming for a 1+1=3 or 4 outcome rather than just 2, focusing on API plus and platform technology for both API and CDMO.